Together with the established functional role of MCL-1 in the pathogenesis of T-LGLL as a pro-survival factor of the malignant clone [2, 9, 31], these results should prompt further studies to systematically evaluate therapeutic strategies targeting both the malignant T-LGLL clone and the broader immune system. The gene discussed is MCL1; the disease is T-cell large granular lymphocyte leukemia.